Rexahn Pharmaceuticals aims to price a public offering of equity units

Financing to be conducted by joint bookrunners Burrill and Maxim Group

By Devika Patel

Knoxville, Tenn., Nov. 28 - Rexahn Pharmaceuticals, Inc. will price a public sale of units, according to a prospectus supplement filed Wednesday with the Securities and Exchange Commission. There is a 45-day greenshoe.

Burrill LLC and Maxim Group LLC are the joint bookrunners.

Rexahn is a biopharmaceutical company based in Rockville, Md.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.